Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Ischemic Heart Disease (IHD) Drugs Market Value Growth And Long-Term Outlook
The ischemic heart disease (ihd) drugs market size has experienced consistent growth in recent years. It is anticipated to expand from $6.65 billion in 2025 to $6.9 billion in 2026, progressing at a compound annual growth rate (CAGR) of 3.7%. This growth witnessed during the historic period stems from the rising prevalence of coronary artery disease, an expanding geriatric population, increasing awareness of cardiovascular health, a significant incidence of lifestyle-related risk factors, and the availability of generic drugs.
The ischemic heart disease (IHD) drugs market size is anticipated to experience consistent expansion over the coming years. It is projected to grow to $7.99 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 3.7%. This growth during the forecast period can be attributed to advancements in precision medicine, the integration of digital health solutions, increased adoption of combination therapies, the development of novel drug delivery systems, and the broadening of telehealth and remote monitoring services. Key trends identified for the forecast period include personalized cardiac therapy, new combination drug formulations, telemedicine-enabled cardiac care, enhanced cardiovascular risk prediction and monitoring, and minimally invasive drug delivery techniques.
Get A Free Sample Report With In-Depth Market Insights:
Ischemic Heart Disease (IHD) Drugs Market Industry Drivers: What’s Behind The Revenue Growth?
The escalating occurrence of heart failure is projected to stimulate the expansion of the ischemic heart disease (IHD) drug market moving forward. Heart failure is a persistent ailment where the heart muscle struggles to pump sufficient blood to satisfy the body’s demand for blood and oxygen. This condition can manifest as fatigue, shortness of breath, and difficulty with routine activities. Ischemic heart disease (IHD) drugs hold a vital position in the management of heart failure. These medications can assist in preventing heart failure by reducing the risk factors and symptoms associated with ischemic heart disease. Ischemic Heart Disease (IHD) drugs operate by inhibiting the heart’s pacemaker activity and are beneficial for heart failure patients exhibiting reduced ejection fractions and elevated resting heart rates, particularly after tolerating a beta-blocker. As an illustration, in September 2023, the Heart Failure Society of America, a US-based organization, reported that 6.7 million Americans over 20 years of age are affected by heart failure (HF), a number anticipated to climb to 8.5 million Americans by 2030. Therefore, the rising incidence of heart failure is a primary factor propelling the growth of the ischemic heart disease (IHD) drug market.
Ischemic Heart Disease (IHD) Drugs Market Segmentation And Category Overview
The ischemic heart disease (ihd) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
#Ischemic Heart Disease (IHD) Drugs Market Growth Trends: What’s Shaping The Future Outlook?
Major companies in the ischemic heart disease (IHD) drugs market are concentrating on advancing regulatory approvals and extending drug indications to bolster therapeutic options and gain a larger market share. For example, in June 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, announced that Camzyos (mavacamten), the first allosteric, selective cardiac myosin inhibitor for treating symptomatic NYHA class II–III obstructive hypertrophic cardiomyopathy (HCM), was approved by the European Commission. In the same year in the U.S., the FDA approved a supplemental new drug application, based on Phase 3 VALOR HCM data, which indicated a significant reduction in eligibility for septal reduction therapy among treated patients. Therefore, the increasing regulatory momentum and expanded labels for myosin inhibitors are stimulating growth in the IHD drug market.
Ischemic Heart Disease (IHD) Drugs Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the ischemic heart disease (ihd) drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., Novitium Pharma LLC
View The Full Ischemic Heart Disease (IHD) Drugs Market Report:
Ischemic Heart Disease (IHD) Drugs Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the ischemic heart disease (IHD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model